Prolonging Progression-Free Survival in Follicular Lymphoma

Slides:

Advertisements

Similar presentations

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.

Advertisements

A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,

May 29 - June 2, 2015 CR Rate at 30 Mos Is a Feasible Surrogate Endpoint for PFS in First-line Follicular Lymphoma Trials CCO Independent Conference Highlights.

Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.

State of the Art in BRCA-Mutated Ovarian Cancer

New Horizons for SMA.

Kahl BS et al. Proc ASH 2011;Abstract LBA-6.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Applying Biosimilars in Hematologic Cancers

Improving Survival in Glioblastoma Multiforme

Targeting FLT3 Mutations in Acute Myeloid Leukemia

Relapsed/Refractory Follicular Lymphoma Conundrums

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

Induction Chemotherapy for Patients With High-Risk or Secondary AML

PARP Inhibitors and Cancer: What Do You Need to Know?

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

R-CHOP for Frontline Follicular Lymphoma

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Jonathan W. Friedberg M.D., M.M.Sc.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Coiffier B et al. Proc ASH 2010;Abstract 857.

Individualizing Care in Ovarian Cancer

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Vitolo U et al. Proc ASH 2011;Abstract 777.

What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,

Stephen Ansell, MD, PhD Mayo Clinic

Fowler NH et al. Proc ASH 2011;Abstract 99.

Salles GA et al. Proc ASCO 2010;Abstract 8004.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Select Therapy In Newly Diagnosed CLL

Follicular lymphoma : To treat or not to treat, and if so when ?

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

PARP Inhibitors.

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Patient Questions and Expert Answers in Psoriasis:

Evaluating BTK Inhibitors in CLL

FLT3 Inhibitors in AML.

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Managing CLL With BTK Inhibitors

From Adjuvant to Metastatic in Melanoma

The Role of Measurable Residual Disease in AML

New Paradigms in M0 CRPC.

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

MRD Analysis in Chronic Lymphocytic Leukemia

Comparative Studies of Biologics in Ulcerative Colitis

Changing Paradigms in Relapsed/Refractory Indolent NHL

Presentation transcript:

Prolonging Progression-Free Survival in Follicular Lymphoma

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Initial Approach to Treating Follicular Lymphoma

Prognostic Value of Post-Induction Therapy PET Scan

Points to Consider

PFS as an Endpoint in FL Maintenance Trials

PRIMA: Randomized, Phase 3 Trial of Maintenance Rituximab in FL

RESORT: Randomized Trial of MR in Low Tumor Burden FL

GALLIUM: Obinutuzumab vs Rituximab in CIT and Maintenance

Maintenance Rituximab After BR Induction

Toxicity of Maintenance Therapy: Expert Observations

RIT as Consolidation Therapy

Maintenance Therapy in Second-Line Setting

Considering Use of Maintenance Therapy: Expert Opinions

Shared Decision-Making

Abbreviations

Abbreviations (cont)